| Bioactivity | Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na+ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research[1][2][3]. |
| Invitro | Atomoxetine (Tomoxetine) (1-100 µM; 0.5-20 seconds; tsA201 cells) interacts with the human heart muscle sodium channel (hNav1.5) in a state and dose-dependent manner[2]. |
| In Vivo | Atomoxetine (Tomoxetine) (0.3-3 mg/kg; i.p.; 0-4 hours; male Sprague-Dawley rats) increases extracellular norepinephrine and dopamine by 3-fold and increases Fos expression in the rat prefrontal cortex[1].Atomoxetine (Tomoxetine) (0.1-5 mg/kg; i.p. and p.o; for 14 days; spontaneously hypertensive rat) can improve behaviors associated with ADHD in rats[3]. Animal Model: |
| Name | Atomoxetine |
| CAS | 83015-26-3 |
| Formula | C17H21NO |
| Molar Mass | 255.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Turner M, et, al. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res. 2013 Apr 15;243:28-37. [2]. Föhr KJ, et, al. Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner. Front Pharmacol. 2021 Feb 25;12:622489. [3]. Bymaster FP, et, al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. |